Company’s 36-month beta value is 1.58.Analysts have differing opinions on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ABEO is 39.59M, and currently, short sellers hold a 6.69% ratio of that floaft. The average trading volume of ABEO on July 04, 2024 was 729.50K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ABEO) stock’s latest price update
Abeona Therapeutics Inc (NASDAQ: ABEO)’s stock price has soared by 5.58 in relation to previous closing price of 4.12. Nevertheless, the company has seen a gain of 6.36% in its stock price over the last five trading days. accesswire.com reported 2024-06-09 that NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ:ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
ABEO’s Market Performance
Abeona Therapeutics Inc (ABEO) has experienced a 6.36% rise in stock performance for the past week, with a -3.76% drop in the past month, and a -45.96% drop in the past quarter. The volatility ratio for the week is 4.23%, and the volatility levels for the past 30 days are at 5.46% for ABEO. The simple moving average for the past 20 days is -0.61% for ABEO’s stock, with a -16.01% simple moving average for the past 200 days.
Analysts’ Opinion of ABEO
Stifel, on the other hand, stated in their research note that they expect to see ABEO reach a price target of $21. The rating they have provided for ABEO stocks is “Buy” according to the report published on May 30th, 2024.
Cantor Fitzgerald gave a rating of “Overweight” to ABEO, setting the target price at $4 in the report published on November 11th of the previous year.
ABEO Trading at 1.05% from the 50-Day Moving Average
After a stumble in the market that brought ABEO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.72% of loss for the given period.
Volatility was left at 5.46%, however, over the last 30 days, the volatility rate increased by 4.23%, as shares surge +0.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.90% lower at present.
During the last 5 trading sessions, ABEO rose by +6.36%, which changed the moving average for the period of 200-days by +7.94% in comparison to the 20-day moving average, which settled at $4.38. In addition, Abeona Therapeutics Inc saw -13.17% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABEO starting from Alvino Mark, who sale 25,890 shares at the price of $4.51 back on Jun 18 ’24. After this action, Alvino Mark now owns 36,926 shares of Abeona Therapeutics Inc, valued at $116,764 using the latest closing price.
Silverstein Christine Berni, the Director of Abeona Therapeutics Inc, sale 25,821 shares at $4.51 during a trade that took place back on Jun 18 ’24, which means that Silverstein Christine Berni is holding 62,063 shares at $116,453 based on the most recent closing price.
Stock Fundamentals for ABEO
Current profitability levels for the company are sitting at:
- -7.98 for the present operating margin
- 0.52 for the gross margin
The net margin for Abeona Therapeutics Inc stands at -12.12. The total capital return value is set at -0.8. Equity return is now at value -1555.11, with -119.62 for asset returns.
Based on Abeona Therapeutics Inc (ABEO), the company’s capital structure generated 1.87 points at debt to capital in total, while cash flow to debt ratio is standing at -2.08. The debt to equity ratio resting at -2.15. The interest coverage ratio of the stock is -39.79.
Currently, EBITDA for the company is -45.0 million with net debt to EBITDA at -0.11. When we switch over and look at the enterprise to sales, we see a ratio of 29.01. The receivables turnover for the company is 2.83for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.61.
Conclusion
In a nutshell, Abeona Therapeutics Inc (ABEO) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
